A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 235
- Registration Number
- NCT04458857
- Locations
- ๐บ๐ธ
Teva Investigational Site 14281, Little Rock, Arkansas, United States
๐บ๐ธTeva Investigational Site 14253, Banning, California, United States
๐บ๐ธTeva Investigational Site 14370, Loma Linda, California, United States
A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT04447729
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04200352
- Locations
- ๐บ๐ธ
Teva Investigational Site 14122, Voorhees, New Jersey, United States
๐บ๐ธTeva Investigational Site 14129, Nashville, Tennessee, United States
๐บ๐ฆTeva Investigational Site 58309, Kyiv, Kyiv Province, Ukraine
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 353
- Registration Number
- NCT04041284
- Locations
- ๐ฉ๐ช
Teva Investigational Site 32734, Leipzig, Germany
๐ฌ๐ทTeva Investigational Site 63075, Athens, Greece
๐บ๐ธTeva Investigational Site 14337, San Diego, California, United States
A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 189
- Registration Number
- NCT03965091
- Locations
- ๐บ๐ธ
Teva Investigational Site 14179, Dallas, Texas, United States
๐บ๐ธTeva Investigational Site 14431, Mesa, Arizona, United States
๐บ๐ธTeva Investigational Site 14164, San Diego, California, United States
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 336
- Registration Number
- NCT03893825
- Locations
- ๐บ๐ธ
Teva Investigational Site 14865, Hialeah, Florida, United States
๐บ๐ธTeva Investigational Site 14770, Marietta, Georgia, United States
๐บ๐ธTeva Investigational Site 14787, Hialeah, Florida, United States
A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT03890666
- Locations
- ๐บ๐ธ
Teva Investigational Site 14197, Aventura, Florida, United States
๐บ๐ธTeva Investigational Site 14302, Los Angeles, California, United States
๐บ๐ธTeva Investigational Site 14195, Savannah, Georgia, United States
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03813238
- Locations
- ๐ฎ๐น
Teva Investigational Site 30216, Pisa, Italy
๐ฎ๐ฑTeva Investigational Site 80147, Zerifin, Israel
๐ฎ๐นTeva Investigational Site 30217, Firenze, Italy
A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03700658
- Locations
- ๐ฉ๐ด
Teva Investigational Site 1, Santo Domingo, Dominican Republic
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT03571256
- Locations
- ๐บ๐ธ
Teva Investigational Site 060-0168, Atlanta, Georgia, United States
๐บ๐ธTeva Investigational Site 060-0155, Chicago, Illinois, United States
๐บ๐ธTeva Investigational Site 060-0166, Gulf Breeze, Florida, United States